Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
NCT Number:
NCT02679144
Phase:
II
Protocol Type:
Prevention
Age Group:
Both
Disease Sites:
Brain and Nervous System
Study Objectives:
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Study Documents
(MUSC NetID required for document access)